What this study is
Pheochromocytomas and paragangliomas are neural crest-derived tumors of the nervous system that are often inherited and genetically heterogeneous. Genetic screening is recommended for patients and their relatives, and can guide clinical decisions. However, a mutation is not found in all cases. The aims of this proposal are to: 1) to map gene(s) involved in pheochromocytoma, and 2) identify genotype-phenotype correlations in patients with pheochromocytoma/paraganglioma of various genetic origins.
What's being tested
- Genetic screening
Intervention · GENETIC
Germline and/or tumor samples will be screened for mutations
Study details
- Sponsor
- The University of Texas Health Science Center at San Antonio
- Conditions
- Pheochromocytoma · Paraganglioma · Inherited Cancer Syndrome · Associated Conditions · Kidney Neoplasms · Bone Cancer · Thyroid Neoplasms · Other Cancer
- Enrolling
- 2,000 people
- Starts
- 2005-10-19
- Est. completion
- 2030-12-31
- Record
- View on ClinicalTrials.gov ↗
Who can join
Sex ALLHealthy volunteers AcceptedYou may qualify if
- Diagnosis of pheochromocytoma and or paraganglioma
- Family member with diagnosis of pheochromocytoma and or paraganglioma
- Diagnosis of a pheochromocytoma- and or paraganglioma-associated condition
- Family member with diagnosis of a pheochromocytoma- and or paraganglioma-associated condition
You can't join if
- Unconfirmed diagnosis of pheochromocytoma and/or paraganglioma or associated condition
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openUniversity of Texas Health Science Center
San Antonio, Texas, United States
- Patricia L Dahia · Contact210-567-4866dahia@uthscsa.edu
Recruiting
Study team
Sponsor
The University of Texas Health Science Center at San Antonio
Study ID HSC20060069H
Principal investigator
Patricia L Dahia, MD, PhD
The University of Texas Health Science Center at San Antonio
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.